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Abstract Convection-enhanced delivery (CED) of highly
stable PEGylated liposomes encapsulating chemothera-
peutic drugs has previously been effective against malig-
nant glioma xenografts. We have developed a novel,
convectable non-PEGylated liposomal formulation that can
be used to encapsulate both the topoisomerase I inhibitor
topotecan (topoCEDTM) and paramagnetic gadodiamide
(gadoCEDTM), providing an ideal basis for real-time
monitoring of drug distribution. Tissue retention of topo-
CED following single CED administration was signifi-
cantly improved relative to free topotecan. At a dose of
10 lg (0.5 mg/ml), topoCED had a half-life in brain of
approximately 1 day and increased the area under the
concentration–time curve (AUC) by 28-fold over free
topotecan (153.8 vs. 5.5 lg day/g). The combination of
topoCED and gadoCED was found to co-convect well in
both naı¨ve rat brain and malignant glioma xenografts
(correlation coefficients 0.97–0.99). In a U87MG cell
assay, the 50% inhibitory concentration (IC50) of topoCED
was approximately 0.8 lM at 48 and 72 h; its concentra-
tion–time curves were similar to free topotecan and unaf-
fected by gadoCED. In a U87MG intracranial rat xenograft
model, a two-dose CED regimen of topoCED co-infused
with gadoCED greatly increased median overall survival at
dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml
(33.0 days) vs. control (20.0 days; P \ 0.0001 for both
comparisons). TopoCED at higher concentrations (1.6 mg/
ml) co-infused with gadoCED showed no evidence of
histopathological changes attributable to either agent. The
positive results of tissue pharmacokinetics, co-convection,
cytotoxicity, efficacy, and lack of toxicity of topoCED in a
clinically meaningful dose range, combined with an ideal
matched-liposome paramagnetic agent, gadoCED, impli-
cates further clinical applications of this therapy in the
treatment of malignant glioma.
Keywords Brain tumor  Convection-enhanced delivery 
Topotecan  Gadodiamide  Liposome
Introduction
Glioblastoma multiforme (GBM) remains one of the most
difficult CNS neoplasms to treat despite intensive multi-
modal therapy. Patients with GBM have a median survival of
12–15 months with surgical resection, radiation and the
addition of systemic chemotherapy and only few patients
survive for more than 2 years [1]. The median survival for
patients with recurrent GBM is approximately 6 months [2].
Topotecan (TPT) is a topoisomerase I inhibitor that is
well established for the treatment of several systemic
cancers including ovarian and small-cell lung cancer.
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Significant activity of TPT in treating malignant gliomas
has been reported [3]. TPT induced a marked growth
inhibition in several human glioma cell lines in vitro [4, 5],
and an apparent supra-additive effect of TPT on ionizing
radiation-induced cytotoxicity was observed in human
GBM cells [4]. Furthermore, TPT showed synergistic
activity with temozolomide in vitro through upregulation
of topoisomerase I in glioma cell lines [6]. Based on these
findings, TPT was tested in a number of clinical studies as
a systemic agent combined with radiotherapy [7–11]; or
paclitaxel [12]. Overall, the results of these studies suggest
that delivering a large enough concentration of systemic
TPT to kill the tumor cells results in unacceptable toxicity.
The observed lack of efficacy is commonly believed to
be primarily due to poor penetration of TPT across the
blood–brain barrier. The blood–brain barrier is disrupted at
the core of the tumor allowing most systemically delivered
chemotherapy agents access to the mostly inactive center
of the tumor, but the barrier remains intact at the growing
tumor margin. It has been clinically observed that 90% of
malignant gliomas recur within 2 cm of an original resec-
tion site [13].
A strategy to overcome the blood–brain barrier is a
direct intracerebral infusion approach called convection-
enhanced delivery (CED). CED employs a positive pres-
sure generating a local pressure gradient to distribute
agents, including therapeutic macromolecules, in the extra-
cellular space. Unlike diffusion, CED is not significantly
influenced by the concentration, molecular weight or par-
ticle size of the agent. In addition, CED leads to repro-
ducible distribution within a given target tissue and results
in high and homogeneous drug concentrations throughout
the volume of distribution (Vd) [14–16].
Bypassing the blood–brain barrier, CED allows tumors
and other target tissues to be exposed to concentrations of
TPT that could not be achieved following systemic appli-
cation, while providing a much wider distribution of the
therapeutic agent across the target site than with simple
diffusion [17, 18]. At the same time, it minimizes systemic
exposure and can therefore be expected to be associated
with fewer systemic side effects [14]. Since its introduc-
tion, CED has shown considerable promise for the treat-
ment of brain tumors with active agents in phase II and III
clinical trials [19].
Liposomal carriers have been shown to provide stable
encapsulation for various anticancer drugs and offer distinct
advantages over unencapsulated agents [18, 20]. Liposomes
are microscopic phospholipid nanoparticles with a bilayered
membrane structure surrounding an aqueous core that can be
used to encapsulate small molecules. Preclinical studies of
liposome-encapsulated camptothecin drugs given via CED
have shown improvement in the sustained release of the
drug, with prolongation of the drug’s half-life leading to
increased exposure of tumor cells to the agent, while
increasing the therapeutic index compared to free drug [20–
22]. Saito and colleagues showed athymic nude rats
implanted with U87MG human glioma cells survived sig-
nificantly longer when they were treated by CED with
PEGylated nanoparticle liposome-encapsulated TPT (nLs-
TPT) as compared to free TPT or empty control liposomes
[21]. Similar observations of a significant survival benefit as
compared to free drug or empty control liposomes delivered
by CED were made in the same tumor model with PEGylated
liposome-encapsulated CPT-11 (irinotecan), another topoi-
somerase I inhibitor [22]. Hence, there is good consistency
within the class of topoisomerase I inhibitors for both anti-
glioma activity and the positive impact on efficacy of
PEGylated liposomal encapsulation when delivered by
CED.
Surface PEGylation of liposomes leads to steric stabil-
ization and is generally thought to reduce the immunoge-
nicity of the vesicles and prolong their circulation in blood
[23]. However, it has recently been demonstrated that
PEGylated liposomes may induce complement activation
which cannot only lead to accelerated blood clearance of
the vesicles upon repeated injection [24], but can also
cause complement activation-related pseudoallergy
(CARPA), an acute and potentially life-threatening Type I
hypersensitivity reaction [25, 26]. Therefore, there is a
strong rationale for the development of a non-PEGylated
liposomal formulation that is suitable for use in a targeted
delivery setting such as CED, which effectively bypasses
the bloodstream but requires minimized tissue affinity [27].
One of the challenging aspects of CED in clinical trials
is the real-time assessment of drug distribution to visualize
tumor coverage and maximize therapeutic effect. Liposo-
mal carriers loaded with gadodiamide (GD) have shown
the feasibility and accuracy of monitoring CED over time
both in tumor and in normal brain using magnetic reso-
nance imaging (MRI) in a rat glioma model [28, 29].
Liposomal encapsulation extends the half-life of GD to
allow visualization up to 72 h [29]. Real-time MRI pro-
vides for accurate calculation of Vd within anatomical
structures and the future ability to correlate the concen-
tration of co-convected liposomal encapsulated therapeutic
agents [30]. Moreover, image-guided CED with liposome-
encapsulated GD allows for real-time alterations in deliv-
ery of liposome-encapsulated therapeutic agents, targeting
the procedure to the pathologically altered brain anatomy
caused by CNS tumors [31].
Critical to the accuracy of tracking a drug during CED
with an imaging tracer is the expression of similar prop-
erties of drug and tracer, including molecular weight,
metabolic degradation in the interstitial space, diffusivity
and receptor binding [32]. We evaluated several non-
PEGylated liposomal formulations of TPT, determining an
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optimal formulation designated topoCEDTM. The same
unique liposomal formulation has been used to encapsulate
GD, designated gadoCEDTM, providing a topoCED-com-
patible imaging tracer.
In this study, we report the statistically highly significant
efficacy of topoCED co-infused by CED with the matching
MRI imaging tracer gadoCED in a U87MG xenograft rat
glioma model. The efficacy results are supported by a
substantial pharmacokinetic advantage of topoCED over
free TPT as well as the excellent cytotoxic potency of to-
poCED with or without adjunct gadoCED. In addition, we
report the combined agents co-convect well in naı¨ve rat
brain and tumor-bearing rat brain with no evidence of
toxicity induced by either agent.
Materials and methods
Test articles
Free TPT formulations were obtained from Glaxo-
SmithKline (Research Triangle Park, NC, USA) and Hisun
Pharmaceuticals (Taizhou City, Zhejiang, China). Empty
control liposomes and drug loaded liposomes were pre-
pared by Northern Lipids Inc (NLI), Burnaby, BC, Canada.
Control liposomes, not loaded with drug, were composed
of distearoylphosphatidylcholine (DSPC), distearoylpho-
sphatidylglycerol (DSPG) and cholesterol (chol) in the
molar ratio of 7:2:1 and a target size of 75–120 nm. Lip-
osomes were prepared by dissolution of all lipids in t-
butanol/ethanol/water (45:45:10, vol/vol) heated to 70C
then added to a 250 mM solution of ammonium sulphate to
generate multilamellar vesicles (MLVs). The MLVs were
maintained at 70C and extruded through a thermobarrel
extruder with 4-stacked polycarbonate filters (Lipex Bio-
membranes Inc, Vancouver, CAN) with 80 nm pores to
yield large unilamellar vesicles (LUVs) with a mean
diameter of 75–120 nm as determined by quasi-elastic light
scattering using a Nicomp 380 ZLS (Nicomp, Santa Bar-
bara, CA, USA) particle sizer following each pass through
the extruder. The LUVs were then diluted with histidine
saline pH 6.0 buffer to a concentration of 5% solvent as the
LUVs were unstable below their phase transition temper-
ature of 55C in 10% solvent. The LUVs were then con-
centrated to approximately 50 mg/ml total lipid by
ultrafiltration and subsequently diafiltered against 10 wash
volumes of 10 mM histidine, 145 mM NaCl buffer to
remove the solvent and exchange the external buffer from
ammonium sulphate to pH 6.0 histidine buffer. This buffer
exchange resulted in the generation of a transmembrane pH
gradient that was used to allow drug loading.
Research or good laboratory practice (GLP) grade TPT,
Hisun Pharmaceuticals (Taizhou City, Zhejiang, China),
was loaded into the liposomes by addition of a 10 mg/ml
solution of TPT in water via a peristaltic pump (Masterflex,
Cole-Palmer, Vernon Hills, IL, USA) to a heated (60C)
suspension of LUV (16.6 mg/ml) in 10 mM histidine,
145 mM sodium chloride (NaCl) buffer and water. TPT
concentrations of 0.67 and 2.0 mg/ml in 5 mM histidine,
145 mM NaCl, pH 6.0, with a 0.1 and 0.3 (w/w) drug:lipid
(D:L) ratio were respectively targeted assuming a 90–95%
drug encapsulation efficiency. The TPT formulation of 0.3
D:L ratio was designated topoCED. A constant total lipid
concentration target of 6.7 mg/ml was to be maintained in
both formulations. Following drug loading, the un-encap-
sulated TPT was removed by diafiltration employing 5-
wash volumes of a 5 mM histidine, 300 mM sucrose pH
6.0 buffer, which also exchanged the external buffer from
NaCl solution to sucrose which acted as a cryo-protectant
to allow freezing the formulation without changing its
physical characteristics. After diafiltration the TPT con-
centration was determined by high-performance liquid
chromatography (HPLC) analysis and the product was
diluted to approximately 2.1 mg/ml. The diluted product
was warmed to 50C and passed through a clarifying cel-
lulose acetate filter and then sterile filtered through two
0.2 lm sterilizing grade filters (Sartobran P, Sartorius AG,
Goettingen, GER) at 35 psi nitrogen pressure connected in
series and collected in a sterile vessel in an aseptic envi-
ronment. The product was aseptically sampled and the TPT
content determined by HPLC analysis. If required, the
product was aseptically diluted with sterile histidine
sucrose buffer to a TPT concentration of 2.0 mg/ml. The
product was then vialed and frozen.
GD for liposomal loading was obtained from Beijing
SHLHT Science & Trade (Beijing, China) for research
grade material or Estech Pharma, Ansan-Si, Gyeonggi-Do,
Korea for GLP grade material. Liposomal GD (gadoCED)
was prepared similarly to topoCED, except that the GD
was passively encapsulated in the liposomes. Following
removal of un-encapsulated GD and solvents by diafiltra-
tion, the final GD encapsulation was C90%. The target GD
content was 5.0 mg/ml ± 10% and a particle size range of
75–120 nm.
Test articles of Ls-TPT were to be stored frozen (-20 to
-30C), and Ls-GD was to be stored refrigerated (2–8C).
Both formulations were stored protected from light.
Research grade material was used only for the tissue phar-
macokinetic experiment, all others utilized GLP material.
Dosing solutions were to be prepared fresh on the day of
dosing and kept at room temperature. Appropriate dilutions
with 5 mM histidine, 145 mM NaCl pH 6.0, 300 mM
sucrose (for tissue pharmacokinetics), or 0.9% saline (all
other tests), of stock solution were to be performed to yield
the desired concentrations. Fresh vials of the stock test article
solution were to be used on each dosing day.
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Tissue pharmacokinetics
Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN)
weighing 250–350 g were housed under aseptic conditions
(Explora BioLabs, LaJolla, CA, USA). The protocol was
approved by the Institutional Animal Care and Use Com-
mittee at Explora BioLabs. Each animal was given a single
20 ll infusion by CED bilaterally into the striatal region of
the brain of TPT as 0.5 mg/ml in three liposomal formu-
lations or free TPT (Hisun Pharmaceuticals). The three
TPT liposomal formulations prepared by NLI were: DSPC/
Chol 0.1 (w/w) D:L ratio; DSPC/DSPG/Chol 0.3 (w/w)
D:L ratio (topoCED); DSPC/DSPG/Chol 0.1 (w/w) D:L
ratio. The three liposomal formulations were co-infused
with gadodiamide at 1.15 mg/ml in a liposome formula-
tion. The animals (n = 3 per group) were sacrificed at 1
and 6 h, 2, 4 and 7 days. The brains were removed, placed
on ice, the striata dissected using a dorsal approach and the
tissue frozen in liquid nitrogen. Equal volume of ice cold
water (1:1 w/w) was added and the thawed tissue was
homogenized (Biospec Products Inc., Bartleville, OK,
USA) mechanically for 2 min and frozen. The frozen
homogenate was shipped to NLI for analysis.
Two hundred microliters of the thawed homogenate
samples were transferred to an Eppendorf tube containing
800 ll of cold methanol (1:4) and centrifuged at 12,000 rpm
for 2–5 min. The supernatant solution, 200 ll was placed in
an autosampler vial for immediate analysis (or stored at
-70C until analysis up to 3 months later). Analysis
was done by NLI using a validated reversed phase HPLC
method. Standards were freshly prepared by extraction of
spiked blank tissue for the lactone form utilizing metha-
nol:water:trifluoroacetic acid (40:60:0.02) and for the car-
boxylate form, 20 mM borate buffer: Methanol (60:40) as
the diluents. Analysis was conducted on a Waters 2690/5
Separation Module and Empower software HPLC system
with a C18 reverse-phase silica column [Phenomenex Inc.
Luna C-18(2) column, 250 mm 9 4.6 mm inner diameter,
5 lm particle size, ambient temperature] preceded by a C18
security guard cartridge (Phenomenex Inc., 4 9 3.0 mm).
Samples were placed in an autosampler tray at 5 ± 3C, a
sample injection volume of 30–50 ll was used, and the
column was eluted at a flow rate of 1.0 ml/min with a mobile
phase consisting of mobile phase A: 3% triethylamine acetic
acid buffer, pH 5.5, (TEAA) and mobile phase B: acetoni-
trile:3% TEAA (50:50). Gradient elution initial 78:22 A:B to
50:50 A:B in 5 min, held 3 min, back to initial in 0.5 min,
total run time 15 min. TPT detected by a Waters 2475 Multi
k fluorescence detector (excitation 380 nm, emission
520 nm). Typical retention time for TPT carboxylate and
lactone forms were 5.5 and 7.5 min, respectively. Total TPT
was determined by addition of the concentrations of the
carboxylate and lactone forms.
Pharmacokinetic parameters that included tissue half-
lives (t1/2) of the drug, and area under the concentration–
time curve (AUC) were all determined by noncompart-
mental pharmacokinetics data analysis utilizing WinNonlin
5.0 (Pharsight Corporation, Mountain View, CA, USA).
Tumor cell lines
Human glioblastoma multiforme cell line U87MG was
used for in vivo and xenograft implant experiments and
obtained from the Brain Tumor Research Center Tissue
Bank at University of California, San Francisco. The cells
were established in T175 Falcon flasks (BD Bioscience,
San Jose, CA, USA). Cells were maintained as monolayers
in Eagle’s minimal essential medium supplemented with
10% fetal calf serum, antibiotics (streptomycin 100 ug/ml,
penicillin 100 U/ml), and nonessential amino acids. Cells
were cultured at 37C in a humidified atmosphere of 95%
air and 5% carbon dioxide. Cells were to be harvested on
the day of tumor inoculation surgery and adjusted to a
concentration of 50,000–100,000 cells/ll.
Cell cytotoxicity assay
Cells from the U87MG cell line above were seeded at
10,000 cells/well in 96-well plates (Corning Inc., NY,
USA), allowed to attach for 24 h, and then exposed to the
following test articles at concentrations of 0.01, 0.1, 1.0
and 10 lM: free TPT (Hisun Pharmaceuticals), free TPT
(GlaxoSmithKline), Ls-TPT (topoCED; NLI), Ls-GD
(gadoCED; NLI) at 200 lM, and topoCED plus gadoCED
at 200 lM, as well as culture medium only as background
control. After exposure to test article, luminescence-based
cell viability assays (CellTiter-GloTM, Promega, Madison,
WI, USA) were conducted at 24, 48 and 72 h. All treat-
ments and control were run in triplicate. The background
absorbance was determined by incubating media with
substrate alone, and subtracting the values from wells
containing cells only.
Animals and intracranial xenograft technique
Congenitally athymic, male, homozygotic, nude rats (rnu/
rnu; 200–275 g) 6–8 weeks of age, were acquired from
Taconic (Germantown, NY, USA) and were housed under
aseptic conditions (Perry Scientific, San Diego, CA, USA).
The protocol was approved by the Institutional Animal
Care and Use Committee at Perry Scientific. For the
intracranial xenograft tumor model, U87MG cells as
described earlier were harvested on the day of tumor
inoculation and resuspended in Hank’s balanced salt
solution without Ca2? and Mg2? (HBSS) for implantation.
A target cell suspension of 5 9 105 cells/10 ll HBSS was
188 J Neurooncol (2009) 95:185–197
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implanted unilaterally into the right striatal region of the
athymic rat brains. Under isoflurane anesthesia, rats were
mounted in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA) with the head positioned by ear bars
and the incisor bar. A longitudinal incision was made in the
skin on top of the skull and blunt dissection was used to
remove connective tissue overlying the skull. A burr-hole
was drilled 0.5 mm anterior and 3.0 mm lateral from the
bregma. U87MG cell suspension was stereotaxically
injected into the right striatum using the appropriate dorso-
ventral coordinates from pial surface (-4.5 to -5 mm with
the incisor bar at -3.3 mm). The volume of injection was
adjusted between 5 and 10 ll to ensure that a total of
5 9 105 cells ± 2.5 9 104 cells were delivered over a
period of 10 min. Following inoculation, the skin was
stapled. The survival time following implantation was
expected to be approximately 0–60 days, wherein the
animal was to be euthanized and the brain harvested.
Evaluation of toxicity
Normal athymic rats, three per group, were evaluated for
potential local toxicity after CED-mediated co-infusion of
topoCED and gadoCED at two dose levels of topoCED.
Rats were monitored daily for general appearance and
behavior (activity, excreta, appearance, grooming, posture,
behavior and weekly food consumption). Animal weights
were reported prior to test article administration and on the
day of necropsy. Two intermediate dose levels of topoCED
between the safe (0.5 mg/ml) and toxic (5.0 mg/ml) con-
centrations established previously were selected [20]. After
CED of a 20 ll solution containing topoCED (0.02 mg,
1.0 mg/ml or 0.032 mg, 1.6 mg/ml) and gadoCED
(0.023 mg, 1.15 mg/ml) into the striatum on days 1 and 4,
rats were euthanized on day 11, and their brains fixed in
4% paraformaldehyde. Fixed brain tissue was subjected to
paraffin sectioning (30 lm), and every fourth section was
stained with hematoxylin and eosin (H&E). The sections,
42 total, were microscopically evaluated for necrosis,
edema, inflammation, hemorrhage, histocytes, pigmented
histocytes, calcification and lipofuscin. Transcardiac blood
samples were taken on day 11 (7 days after the last treat-
ment) prior to necropsy for determination of TPT and GD
plasma levels.
Topotecan and gadodiamide plasma levels
Blood samples for plasma TPT and GD extraction and
measurement were centrifuged to separate plasma. Four-
hundred microliters of the supernatant was added to 2.0 ml
Eppendorf tubes containing 1.6 ml cold methanol kept on ice
and vortexed. Plasma extracts were stored at -70C until
shipment for analysis using a validated reversed phase HPLC
method by NLI as described above for determination of TPT
levels in brain tissue. For GD levels, the plasma extracts were
analyzed by inductively coupled plasma mass spectroscopy
by a contract laboratory, Cantest (Burnaby, BC, Canada).
TopoCED therapy by CED in the U87MG intracranial
xenograft model
Thirty adult male athymic rats were implanted with
U87MG tumor cells as previously described under Animals
and Intracranial Xenograft Technique. The protocol was
approved by the Institutional Animal Care and Use Com-
mittee at Perry Scientific. Animals treated on days 5 and 8
after tumor implantation were randomly assigned into 3
groups: (1) CED of topoCED 0.5 mg/ml plus gadoCED
1.15 mg/ml (n = 10), (2) CED of topoCED 1.0 mg/ml plus
gadoCED 1.15 mg/ml (n = 10), and (3) control (no treat-
ment, n = 10). CED of 20 ll of the specified test article
was performed for each group. Test articles were delivered
by CED as described previously [21]. Infusions were per-
formed at the same depth as that used for the tumor cell
inoculation and were done on days 5 and 8 following
inoculation. A complete gross necropsy of all animals
found dead or sacrificed was performed as well as brain
fixation and sectioning as previously described under
Evaluation of Toxicity.
Distribution of topoCED and gadoCED in normal
rodent brain and U87MG brain tumor xenografts
Normal athymic rats (n = 3) or athymic rats implanted
with U87MG (n = 4) tumor cells as previously described
under Animals and Intracranial Xenograft Technique were
used. The protocol was approved by the Institutional Ani-
mal Care and Use Committee at Perry Scientific. Different
fluorophores were used to label topoCED and gadoCED in
order to allow differential microscopic fluorescence/lumi-
nescence, marina blue-DHPE (1,2-dehexadecanoyl-sn-
glycero-3-phosphoethanolamine) (Invitrogen, Carlsbad,
CA) for topoCED and rhodamine-PE (phosphoethanol-
amine) (Invitrogen, Carlsbad, CA) for gadoCED. Marina
blue-DHPE and rhodamine-PE labeled liposomes were
prepared similarly to topoCED and gadoCED, respectively,
as previously described under Test Articles, with the fluo-
rophores added to the lipid powder at the same time as the
solvent solution in an amount based on a DSPC:DSPG:
cholesterol:fluorophore molar ratio of 69.7:20:10:0.3. CED
of 20 ll over 40 min was performed bilaterally into the
striatum 10 days after implantation for the tumor group
(right side tumor implanted only), and on day 1 for the
naı¨ve group. Animals were euthanized immediately after
the infusion procedure. Brains were fixed in 4% parafor-
maldehyde and cut into 30–40 lm sections on a cryostat.
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Every fifth section was collected on a glass slide and cover
slipped with Fluoromount-G for analysis. The convection
profiles and tissue distribution of both topoCED and gad-
oCED were determined by means of fluorescence micros-
copy, and the Vd of both marina blue-DHPE and
rhodamine-PE fluorophores in the sections were calculated
using National Institute of Health image software. The
CORR procedure in Statistical Analysis System (SAS) was
used to produce Pearson correlation coefficients.
Statistical analysis
Results for the survival studies are expressed as a Kaplan–
Meier (KM) survival analysis which was performed using a
log rank statistic for comparative purposes. Median sur-
vival (MS) times were presented based on the KM curve.
Separate analyses of survival were performed with eutha-
nized animals considered as either uncensored (dead) and
censored (alive).
Results
Tissue pharmacokinetics of liposomal topotecan
co-administered with liposomal gadodiamide by CED
in rat brain
Three formulations of liposomal TPT (NLI) containing
0.01 mg TPT, each combined with 0.023 mg GD in
separate liposomes, as well as free TPT alone, were
infused by a single CED treatment (20 ll over 40 min)
into the brains of adult rats. Brain tissue levels of TPT
were determined by a validated HPLC method at various
times after infusion (Fig. 1). The highest brain tissue
concentrations were achieved with the DSPC/DSPG/Chol
0.3 D:L ratio liposomal formulation of TPT, while the
other two liposomal formulations performed similarly to
free TPT. A brain tissue concentration range of 1.24–
146.4 lM over the first 96 h was determined for the
DSPC/DSPG/Chol 0.3 D:L ratio liposomal formulation.
Due to the limited number of data points, as each data
point required sacrificing 3 animals, meaningful PK
variables could not be calculated with the exception of
AUC. The AUC(0–last) was markedly larger for the DSPC/
DSPG/Chol 0.3 D:L ratio formulation (153.8 lg day/g)
compared to DSPC/Chol 0.1 and DSPC/DSPG/Chol 0.1
(38.3 and 68.2 lg day/g, respectively), and free TPT
(5.5 lg day/g). All the liposomal formulations yielded
half-lives in the range of 1 day while the half-life of free
topotecan was much shorter. Based on these results, the
DSPC/DSPG/Chol 0.3 D:L ratio formulation of TPT was
selected for further study and designated topoCED.
Distribution of topoCED co-infused with gadoCED
in normal rat brain and U87MG brain tumor xenografts
Co-convection by CED of topoCED with gadoCED was
tested in both normal brain tissue and tumor xenograft
implanted brain tissue in athymic rats utilizing different
fluorophores to label topoCED and gadoCED in order to
allow differential microscopic fluorescence/luminescence.
Representative slides of staining are shown in Fig. 2.
Fig. 1 Tissue pharmacokinetics
of nanoliposomal TPT in three
unique formulations co-
administered with GD in a
liposomal formulation plus free
TPT in the normal adult rat
brain after single CED infusion.
All values are mg TPT per gram
of brain tissue versus time after
CED of 20 ll infusate. Drug
concentrations were determined
by HPLC assay for total TPT.
Values are means ± SD of
three animals per time point
190 J Neurooncol (2009) 95:185–197
123
In naı¨ve brain tissue of normal athymic rats (n = 3), the
Vd values of topoCED-marina blue DHPE were in a tight
range with a mean of 38.5 ± 5.6 mm3 and a corresponding
Vd to volume of infusion (Vi) ratio of 1.9. In contrast, the Vd
values were markedly smaller and generally more variable
in the tumor-implanted animals (n = 4), with means of
31.2 ± 6.9 mm3 in right hemisphere tumor tissue and
21.4 ± 10.3 mm3 in left hemisphere naı¨ve brain tissue. The
corresponding Vd:Vi ratios were 1.6 in tumor tissue and 1.1
in naı¨ve brain tissue in the tumor-implanted animals. The
results for gadoCED-rhodamine-PE were remarkably con-
sistent with those for topoCED-marina blue DHPE. Spe-
cifically, the mean Vd value was 39.3 ± 5.3 mm
3 in naı¨ve
brain tissue of normal athymic rats, with a corresponding
Vd:Vi ratio of 2.0. In the tumor-implanted animals, the
mean Vd value was 32.2 ± 8.1 mm
3 in right hemisphere
tumor tissue and 22.3 ± 9.2 mm3 in left hemisphere naı¨ve
brain tissue. The corresponding Vd:Vi ratio was 1.6 in tumor
tissue and 1.1 in naı¨ve brain tissue. Consistent with the
individual distribution results, the correlation between the
mean Vd values of topoCED-marina blue DHPE and gad-
oCED-rhodamine-PE was excellent in all treatment groups
(range: 0.97–0.99), and there were no appreciable differ-
ences in the correlation between tissue types (naı¨ve brain
tissue vs. tumor tissue). Graphic representation of the
results is shown in Fig. 3.
Cell cytotoxicity assay
The cell survival fractions by concentration of TPT after
24, 48 and 72 h treatment of U87MG cells are presented
in Fig. 4, panels A, B, and C, respectively. Cytotoxic
activity and potency of free TPT from two different
sources (GlaxoSmithKline and Hisun Pharmaceutical)
and of topoCED appeared very similar at comparable
concentrations (0.01, 0.1, 1.0 and 10 lM) and time
points (24, 48 and 72 h). The in vitro IC50 of topoCED
at 48 and 72 h was approximately 0.8 lM supporting the
potential efficacy of this liposomal TPT formulation.
GadoCED alone or co-infused with topoCED did not
appear to result in cytotoxicity, or affect the cytotoxicity
of topoCED, even at the very high concentration of
200 lM.
Effect of topoCED co-infused with gadoCED
in U87MG brain tumor xenografts
Survival in rats with intracranial U87MG brain tumor xe-
nografts treated 5 and 8 days after cell implantation was
studied. The main efficacy analysis considered euthanized
animals as uncensored (dead). Survival curves by treatment
group are presented in Fig. 5. Control rats (n = 10) that
received no treatment or procedure died or were euthanized
19–21 days after tumor implantation due to neurological
symptoms indicative of tumor progression. Median sur-
vival (MS) for this group was 20.0 days (95% CI, 19–21).
Rats in each treatment group, 10 each, of low dose topo-
CED, 0.5 mg/ml plus gadoCED 1.15 mg/ml, or high dose
topoCED, 1.0 mg/ml plus gadoCED 1.15 mg/ml, showed a
significant improvement in survival versus control
(P \ 0.0001 for both groups) with a MS of 29.5 (95% CI,
27–33) and 33.0 days (95% CI, 31–40), respectively. MS
Fig. 2 Representative slides of
staining of topoCED-marina
blue liposomes (green stain) and
gadoCED-rhodamine labeled
liposomes (red stain) co-infused
as 20 ll by CED. a From rat
7644 normal brain tissue, and b
from rat 7622 tumor implanted
tissue
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was increased by 65% for the high dose group and 48% for
the low dose group over the control group. MS for the
active treatment groups combined was 31.5 (95% CI, 30–
36) days, a 58% increase, and also statistically significant
when compared to the control group (P \ 0.0001).
Although a dose/concentration response trend was
observed with a hazard ratio of 0.567 (95% CI, 0.23–1.38),
the difference between the two actively treated groups did
not reach the level of statistical significance (0.5 vs.
1.0 mg/ml, P = 0.215).
A secondary efficacy analysis was performed consider-
ing euthanized animals as censored. This analysis was
consistent with main analysis, revealing a longer survival
for active-treated animals compared to control animals,
with median survivals of 48.0 (95% CI, not determined) in
the high dose topoCED group (9 of 10 animals euthanized),
33.0 (95% CI, 30.0–48.0) in the low dose topoCED group
(5 of 10 animals euthanized), and 23.0 (95% CI, 20.0–23.0)
days in the control group (6 of 10 animals euthanized).
These differences were also statistically significant when
compared to control (high dose topoCED vs. control,
P = 0.0014; low dose topoCED vs. control, P = 0.0014).
Median survival for the active-treated groups combined
was 48.0 (95% CI, 36.0–48.0) days and also statistically
significant when compared to controls (P \ 0.0001).
Overall gross necropsy findings included abnormalities
involving the brain in the majority of the animals. The
brain abnormalities were consistent with the tumor xeno-
graft in place including hemispheric enlargement ipsilateral
to the tumor xenograft and tumor often protruding through
the cannula track with mass effect. Representative histol-
ogy showing control, low-dose treated and high-dose
treated rats bearing U87MG xenograft 20, 27 and 42 days
after implant, respectively, are shown in Fig. 6a–c.
Evaluation of toxicity
Toxicity of higher doses of topoCED (1.0 or 1.6 mg/ml) in
combination with gadoCED 1.15 mg/ml were tested in
naı¨ve rat brains prior to the conduct of the efficacy study to
ensure tolerability of the selected efficacy study doses. No
significant toxicity due to the agents was detected 11 days
after CED infusion of 20 ll into the striatum on days 1 and
4. Relevant findings revealed by microscopic examination
included foci of recent hemorrhage, mainly mild and
focally moderate in degree, extending from the cortex into
the white matter as well as the basal ganglia, and situated in
or around the sections containing the cannula tract. In no
case were there more than two sections showing hemor-
rhage. In addition, areas of histiocytic infiltration were
localized with a similar distribution. Some of the histio-
cytes contained golden pigment, possibly hemosiderin.
Negative findings included no evidence of significant
neuronal loss or changes in glial cells such as gliosis or
frank necrosis. The meninges, blood vessels and ventricles
all appeared within normal limits within all sections. There
was no evidence of significant edema, acute or chronic
inflammation, calcification, or coagulative necrosis. Fur-
ther, there were no significant differences in histologic
findings between the two dose groups within the study.
Fig. 3 Volume of distribution
of topoCED-marina blue DPHE
co-infused with gadoCED-
rhodamine-PE by CED (20 ll
infused in each hemisphere) in
naive rodent brain (n = 3) and
U87MG xenograft rodent brain
(normal left hemisphere, tumor
right hemisphere, n = 4).
Pearson’s correlation
coefficients (r) confirm good co-
convection
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Plasma extract measurements at day 11 (7 days after the
last infusion) revealed both topotecan and gadodiamide
levels were either absent or below the lower limit of
quantification of the assay.
Discussion
Since the introduction of CED, this technique has shown
considerable promise for the treatment of brain tumors with
active agents in phase II and III clinical trials [19],
although the phase III results did not meet their primary
endpoints of overall survival [33, 34]. The failed phase III
CED studies did not employ an adjunct agent for the real-
time monitoring of drug distribution in the general study
population, which may be an important factor explaining
these disappointing study outcomes. The future success of
CED-based delivery technology for clinical application
will require continued refinements and improvements.
These include an effective formulation of an active thera-
peutic agent with desirable convection properties and the
ability to monitor delivery to the target tissue thereby
increasing efficacy and reducing toxicity in the clinic [35].
Several groups have reported improved convection and
pharmacologic properties of camptothecins, which are
known to be active against malignant glioma, by encap-
sulation into PEGylated liposomes [21, 22, 36]. TPT is a
good therapeutic candidate for GBM based on its known
cytotoxic activity against various glioma cell lines in vitro
and its preferential antiangiogenic effects at low concen-
trations [37]. A stable PEGylated liposomal formulation of
TPT delivered by CED was shown to be effective in the
U87MG intracranial rat xenograft model [21]. However,
while PEGylation was found to enhance the distribution of
liposomes given via CED by reducing their tissue affinity
[27], recent reports about PEG-induced complement acti-
vation raised concerns about the safety of PEGylated for-
mulations [24–26]. The feasibility and accuracy of
monitoring CED over time was shown with PEGylated
liposomal carriers loaded with gadodiamide in a rat glioma
model both in tumor and in normal brain [28, 29, 38]. An
ideal imaging tracer should possess convection properties
similar to the therapeutic agent to ensure tracking accuracy
[32].
Building on this work, we have developed and opti-
mized a non-PEGylated liposomal DSPC/DSPG/Chol for-
mulation of TPT (topoCED) and matched liposomal MR
imaging tracer GD (gadoCED). This novel, convectable
formulation provides an ideal basis for real-time monitor-
ing of TPT distribution. Our study results demonstrate
positive tissue pharmacokinetics, co-convection, cytotox-
icity, efficacy, and lack of toxicity of topoCED with gad-
oCED, in a clinically meaningful dose range.
Tissue retention of topoCED following single CED
administration was significantly improved relative to free
topotecan. At a dose of 10 lg (0.5 mg/ml), topoCED had a
half-life in brain of approximately 1 day and increased the
area under the concentration–time curve (AUC) by 28-fold
over free topotecan (153.8 vs. 5.5 lg day/g; see Fig. 1).
Fig. 4 Cell survival fraction of U87MG cells versus TPT concentra-
tion at 24, 48 and 72 h exposure (a–c, respectively). U87MG cells
were exposed to culture medium (control), Ls-GD (gadoCED;
200 lM), TPT concentrations of 0.01, 0.1, 1.0 and 10 lM as free
TPT (Hisun Pharmaceuticals), free TPT (GlaxoSmithKline), topo-
CED, and combination topoCED and gadoCED (200 lM). Cells were
analyzed by luminescence-based cell viability assays as described in
Materials and Methods
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The substantial AUC advantage of topoCED over free TPT
supports the efficacy results.
Co-convection of topoCED combined with gadoCED
was tested in both naı¨ve rat brain tissue and U87MG
intracranial rodent xenograft tumor tissue utilizing differ-
ent fluorophores to label topoCED (marina blue labeled
liposomes) and gadoCED (rhodamine labeled liposomes)
in order to allow differential microscopic fluorescence/
luminescence (see Fig. 2). Reliable and consistent drug
distribution of both agents was demonstrated with Vd:Vi
ratios of 1.9 in normal brain. The distribution of topoCED
in naı¨ve rat brain tissue is similar to liposome infusion by
CED in normal non-human primate brain (Vd:Vi ratio of 2)
[38], and in normal canine brain (Vd:Vi ratio range of
Fig. 5 Kaplan–Meier survival
curve of two topoCED
treatment groups (0.5 and
1.0 mg/ml) infused by CED
(20 ll) on days 5 and 8 after
U87MB cell implantation
versus control. Both treatment
groups showed a significant
improvement in survival versus
control (P \ 0.0001 for both
groups)
Fig. 6 Representative histology
of animals used in this study. a
Shows control rat (7640)
bearing U87MG xenograft
20 days after implant, rat
euthanized; b shows
2 9 0.5 mg/ml topoCED
treated rat (7632) bearing
U87MG xenograft 27 days after
implant, rat euthanized; c shows
2 9 1.0 mg/ml topoCED
treated rat (7609) bearing
U87MG xenograft 42 days after
implant, rat euthanized
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1.2–3.4) [39]. In the tumor-implanted animals, the corre-
sponding Vd:Vi ratios were 1.6 in tumor tissue and 1.1 in
naı¨ve brain tissue, right and left hemispheres respectively.
CED fluid dynamics appear to be impacted by intracranial
pressure, with high intracranial pressure due to excessive
tumor growth leading to impaired drug distribution in both
naı¨ve brain tissue and tumor tissue in the tumor implanted
animals. Excellent co-convection of topoCED and gado-
CED was observed in both tissue types with correlation
coefficients between 0.97 and 0.99 (see Fig. 3).
TopoCED demonstrated excellent potency in a U87MG
cell assay; its concentration–time curves were similar to
free topotecan (see Fig. 4). The IC50 of topoCED was
approximately 0.8 lM at 48 and 72 h, which is well below
the brain tissue concentration range of 1.24–146.4 lM over
the first 96 h that was observed in the pharmacokinetic
study. GadoCED alone or co-infused with topoCED did not
appear to result in additive or synergistic cytotoxicity even
at the very high concentration of 200 lM.
A clear and consistent survival advantage as compared to
untreated controls was demonstrated with a two-dose CED
regimen of topoCED at two dose levels (1.0 and 0.5 mg/ml)
in conjunction with gadoCED (1.15 mg/ml) using the
in vivo U87MG intracranial rat xenograft model. The
findings showed both topoCED dose levels resulted in a
highly statistically significant increase in overall survival
(P \ 0.0001) when compared to controls (see Fig. 5).
Median survival was increased by 65% for the high dose
group (33.0 vs. 20 days) and by 48% for the low dose group
(29.5 vs. 20 days) over the control group. In the low dose
group the effect size was slightly more moderate than in the
high dose group, thus suggestive of a dose/concentration
dependent effect. Similar findings were observed when the
survival analysis was performed with euthanized animals
considered as censored which is a more conservative
assessment method preventing any potential overestimation
of the true effect size of topoCED while possibly underes-
timating that effect. The results of the secondary efficacy
analysis were still highly statistically significant and strongly
support the primary efficacy analysis findings in which
euthanized animals were considered as uncensored.
The overall efficacy study findings, although highly sta-
tistically significant, differ somewhat from efficacy findings
reported for animals receiving a PEGylated nanoparticle
liposome-TPT (nLs-TPT) formulation reported by Saito and
colleagues [21]. Also, Yamashita and colleagues reported a
MS of 27.5 days for animals receiving the same nLs-TPT
formulation at a dose of 0.25 mg/ml [40]. While these
seeming differences between the study results may be
attributable to differences between the liposomal formula-
tions, they may also be due to a number of other factors
including differences in the viability of the cell lines and
technical factors leading to variable tumor coverage. The
relative roles of these factors can only be determined in a
direct head to head comparison of the different formulations
in the same model.
TopoCED at higher concentrations (1.6 mg/ml) co-
infused with gadoCED (1.15 mg/ml) in naı¨ve brain tissue
appeared to be safe with no evidence of histopathological
changes within targeted regions that were attributable to
either agent in a pilot toxicology study in rats. Small areas
of acute hemorrhage were mostly localized along the
cannula tract and presumably related to the experimental
procedure and drug delivery system. Gross and micro-
scopic changes related to the delivery technique including
cannula insertion and CED have been described previously
and the changes observed in this study are consistent with
the delivery technique employed [16]. A concentration of
5.0 mg/ml TPT in the nLs-TPT formulation was previously
reported to be toxic while 0.5 mg/ml was well tolerated
[21]. In addition, TPT and GD plasma levels 11 days after
infusion were below the lower level of quantitation for
the assay consistent with the delivery method and drug
properties.
In conclusion, TPT has been previously shown to be an
active agent against malignant glioma. Direct intracerebral
administration by CED lowers the systemic exposure sig-
nificantly as compared to intravenous applications resulting
in fewer systemic adverse events and thereby improvement
of the safety of the drug. We have developed topoCED and
gadoCED, unique non-PEGylated nanoparticle liposomal
formulations of TPT and GD, respectively, and demon-
strated desirable TPT pharmacokinetic properties that
resulted in significant efficacy using the in vivo U87MG
intracranial rodent xenograft model when the two agents
were co-infused by CED. Excellent co-convection of the
two agents indicates gadoCED will provide a means to
visualize topoCED infusion during CED reducing the risk
of leakage into the CNS while improving efficacy. The
effective dose range is well tolerated and cleared within
7 days. The overall results reported here warrant further
investigation of topoCED co-administered with gadoCED
by CED in non-human primate tumor models with the goal
of treating patients with malignant glioma in the near
future.
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